X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
A recent peer-reviewed paper details Bexson's subcutaneous ketamine formulation technique for BB106, which allows fine tuning to subcutaneous tissue pH and osmolality for compatibility.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Neurology Product Name: BB106
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2022
Details:
The USPTO has granted Bexson U.S Patent, describing pharmaceutical formulations and treatment methods including BB106. BB106 is formulated for subcutaneous delivery, which could make ketamine-based pain management a viable alternative to opioids.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Neurology Product Name: BB106
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2021
Details:
Funding will support the company through pre-clinical and GMP manufacturing scale up for its proprietary ketamine formulation, BB106, and the development of a wearable delivery device with leading medical device manufacturer, Stevanato Group.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Neurology Product Name: BB106
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Noetic Psychedelic Fund
Deal Size: $4.8 million Upfront Cash: Undisclosed
Deal Type: Series A Financing February 02, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
